Lund­beck reads last rites on an­oth­er failed PhI­II Alzheimer’s pro­gram

Lund­beck and Ot­su­ka have racked up two more Phase III flops for their 5-HT6 an­tag­o­nist idalopir­dine, set­ting up cor­po­rate last rites for yet an­oth­er failed Alzheimer’s drug.

The Dan­ish biotech said in their Q4 roundup to­day that “the ef­fi­ca­cy pro­file with idalopir­dine ob­served in these stud­ies and in the (first) STARSHINE study do not demon­strate ef­fi­ca­cy to sup­port a reg­u­la­to­ry sub­mis­sion.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.